Korea:006280

GC Pharma lights up to celebrate 'World Hemophilia Day'

YONGIN, South Korea, April 17, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, participate in campaign to celebrate World Hemophilia Day.

2020-04-17 21:00 1529

GC Pharma Reports Full Year 2019 Results

All consolidated entities revenues grew plus compared to prior year YONGIN, South Korea, Feb. 12, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December 201...

2020-02-12 22:00 9134

GC Pharma Reports Q3 2019 Results

YONGIN, South Korea, Oct. 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedSeptember 30, 2019. Key Figures Q3 2019(1) Growth(1) Total revenues K...

2019-10-30 21:00 5395

GC Pharma Reports Q2 2019 Results

YONGIN, South Korea, July 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedJune 30, 2019. Key Figures Q2 2019(1) Growth(1) Total revenues KRW 35...

2019-07-30 22:31 7182

GC Pharma Reports Q1 2019 Results

YONGIN, South Korea, April 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedMarch 31, 2019. Key Figures Q1 2018(1) Growth(1) Total revenues KRW 2...

2019-04-30 15:37 6510

Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug

YONGIN, South Korea, April 4, 2019 /PRNewswire/ -- Clinigen K.K. and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today announced an exclusive licensing agreement inJapan to commercialize Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used...

2019-04-04 11:38 2209

GC Pharma Reports Full Year 2018 Results

Delivers Continued Momentum in 2018 Through Broadly-based Sales Growth YONGIN, South Korea, Feb. 12, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December ...

2019-02-12 22:00 10314

GC Pharma Reports Q3 2018 Results

YONGIN, South Korea, Oct. 30, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedSeptember 30, 2018. Key Figures Q3 2018(1) Growth(1) Total revenues K...

2018-10-30 16:33 613

GC Pharma Reports Q2 2018 Results

YONGIN, South Korea, July 31, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedJune 30, 2018. Key Figures Q2 2018(1) Growth(1) Total revenues KRW 34...

2018-08-01 12:24 607

GC Pharma to Establish Curevo - a Seattle-based New Company Dedicated to Development of New Vaccines

YONGIN, South Korea, May 20, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced the establishment of Curevo Inc. ("Curevo"). The newly establishedSeattle-based company's goal is to support GC Pharma's...

2018-05-21 07:00 907

GC Pharma Reports Q1 2018 Results

YONGIN, South Korea, April 27, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedMarch 31, 2018.   Key Figures Q1 2018(1) Growth(1) Total revenues K...

2018-04-27 16:10 715

GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

YONGIN, South Korea, Feb. 14, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm") (SEHK: 0950) ...

2018-02-14 13:19 1375

GC Pharma Reports Full Year 2017 Results

YONGIN, South Korea, Feb. 4, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December 2017. Key Figures Full Year 2017 Growth(1) Total revenues KRW 1,287...

2018-02-05 10:46 525

GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B

YONGIN, South Korea, Jan. 18, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced that it will proceed with a Phase 2/3 clinical trial for GC1102 (also known as Hepabig-gene), the company's investigati...

2018-01-18 08:00 1268